{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:12:20Z","timestamp":1771567940813,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejphar.2023.175946","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T20:51:22Z","timestamp":1691009482000},"page":"175946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model"],"prefix":"10.1016","volume":"957","author":[{"given":"Yun Kyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Jung","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Yoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyen Chung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hak Chul","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-8116","authenticated-orcid":false,"given":"Sung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175946_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cmet.2019.05.006","article-title":"Acceleration of beta cell aging determines diabetes and senolysis improves disease outcomes","volume":"30","author":"Aguayo-Mazzucato","year":"2019","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2023.175946_bib2","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin treatment is associated with improved beta-cell function in type 2 diabetes mellitus","volume":"103","author":"Al Jobori","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.175946_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4093\/dmj.2020.0272","article-title":"Lobeglitazone: a novel thiazolidinedione for the management of type 2 diabetes mellitus","volume":"45","author":"Bae","year":"2021","journal-title":"Diabetes Metab. J"},{"key":"10.1016\/j.ejphar.2023.175946_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150756","article-title":"Dapagliflozin, a sodium-glucose Co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice","volume":"11","author":"Chiba","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175946_bib5","article-title":"Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice","volume":"13","author":"Choi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175946_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4292509","article-title":"Treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice","volume":"2018","author":"Choung","year":"2018","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejphar.2023.175946_bib7","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1210\/jc.2011-0246","article-title":"Preservation of beta-cell function: the key to diabetes prevention","volume":"96","author":"DeFronzo","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.175946_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3803\/EnM.2021.1026","article-title":"Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus","volume":"36","author":"Ha","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2023.175946_bib9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.175946_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217833","article-title":"Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection","volume":"21","author":"Hou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.175946_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11914-020-00609-z","article-title":"Diabetes and bone fragility: SGLT2 inhibitor use in the context of renal and cardiovascular benefits","volume":"18","author":"Jackson","year":"2020","journal-title":"Curr. Osteoporos. Rep."},{"issue":"9","key":"10.1016\/j.ejphar.2023.175946_bib12","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1002\/jcp.30316","article-title":"Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK\/mTOR signaling pathway in obese rats","volume":"236","author":"Jaikumkao","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2023.175946_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.clinthera.2020.01.003","article-title":"Evaluation of the pharmacokinetic interaction between lobeglitazone and dapagliflozin at steady state","volume":"42","author":"Jang","year":"2020","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejphar.2023.175946_bib14","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1172\/JCI11705","article-title":"Unraveling the mechanism of action of thiazolidinediones","volume":"106","author":"Kahn","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2023.175946_bib15","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.175946_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2021.100082","article-title":"Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: do they have a role in primary prevention?","volume":"10","author":"Kale","year":"2021","journal-title":"Metabol. Open"},{"key":"10.1016\/j.ejphar.2023.175946_bib17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ijo.2017.222","article-title":"Effects of lobeglitazone, a novel thiazolidinedione, on adipose tissue remodeling and brown and beige adipose tissue development in db\/db mice","volume":"42","author":"Kim","year":"2018","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2023.175946_bib18","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2023.175946_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109123","article-title":"Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study","volume":"182","author":"Ku","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2023.175946_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40360-017-0169-y","article-title":"Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation","volume":"18","author":"Ku","year":"2017","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2023.175946_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diabres.2019.04.006","article-title":"The direct effect of lobeglitazone, a new thiazolidinedione, on pancreatic beta cells: a comparison with other thiazolidinediones","volume":"151","author":"Kwon","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2023.175946_bib22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4093\/dmj.2020.0010","article-title":"Korean diabetes association fatty liver research, G., 2020. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the fatty liver research group of the Korean diabetes association","volume":"44","author":"Lee","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.ejphar.2023.175946_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018298","article-title":"Direct cardiac actions of the sodium glucose Co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure","volume":"10","author":"Li","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2023.175946_bib24","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1530\/JOE-16-0211","article-title":"Adipose tissue in control of metabolism","volume":"231","author":"Luo","year":"2016","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejphar.2023.175946_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000496617","article-title":"Effect of dapagliflozin treatment on the expression of renal sodium transporters\/channels on high-fat diet diabetic mice","volume":"142","author":"Ma","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.ejphar.2023.175946_bib26","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/jat.2918","article-title":"CKD-501, a novel selective PPARgamma agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks","volume":"34","author":"Moon","year":"2014","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejphar.2023.175946_bib27","doi-asserted-by":"crossref","first-page":"8805","DOI":"10.1038\/s41598-018-27181-y","article-title":"Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes","volume":"8","author":"Nishitani","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.175946_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56684-5","article-title":"Butyrate attenuated fat gain through gut microbiota modulation in db\/db mice following dapagliflozin treatment","volume":"9","author":"Oh","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.175946_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114009","article-title":"Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance","volume":"177","author":"Tanday","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175946_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101158","article-title":"Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: a step toward personalised diabetes treatment?","volume":"46","author":"Veelen","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2023.175946_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2023.175946_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154324","article-title":"Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice","volume":"111","author":"Wei","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2023.175946_bib33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/DMSO.S117982","article-title":"Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin","volume":"10","author":"Yu","year":"2017","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923004582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923004582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:27:38Z","timestamp":1762144058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923004582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":33,"alternative-id":["S0014299923004582"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175946","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175946"}}